ALS clinical trial recruitment built on global advocacy and registry partnerships, proven across Phase 2 and Phase 3 trials.

We deliver enrollment-ready patients to your sites and support families through pre-screening, fast enough to keep pace with ALS disease progression.

Talk to our ALS teamSee how it works →
~100
ALS patients enrolled globally
on a completed Phase 3 study
~30%
Of total enrollment
on a highly competitive Phase 3 ALS study
~$1.1M
Sponsor enrollment savings
in enrollment cost delivered to the sponsor
10+
Countries enrolled
US, EU, Nordics (incl. Sweden), Australia

Understanding ALS as a Clinical Trial Indication

Amyotrophic lateral sclerosis (ALS) affects approximately 30,000 people in the United States and an estimated 450,000 globally, with a median survival of two to five years from diagnosis. ALS trials face a structural enrollment challenge no other neuromuscular indication shares at the same intensity: the eligible patient pool is small, geographically dispersed across countries, and shrinking in real time as patients progress. Every week of recruitment delay narrows the protocol's eligible window. Patients and families know this, and they make participation decisions together, often quickly, when a trial is presented to them by a trusted source.

Generic third-party recruitment campaigns do not solve ALS. National ALS advocacy organizations, ALS-specific patient registries, and motor neuron disease (MND) clinical networks are where patients are concentrated, informed, and actively considering research as a treatment option. The Nordic countries, Sweden in particular, operate some of the most active ALS registries in the world, which is why a globally-coordinated ALS recruitment strategy that includes Northern European registry partnerships consistently outperforms a US-only digital approach.

Leapcure recruits ALS patients through the global network of advocacy organizations, registries, and clinical communities those patients and families already trust. We activate ALS-specific partnerships across North America, Europe, the Nordics, and Australia; deploy precision digital aligned to site capacity; and support patients and caregivers through pre-screening with the speed ALS demands. In a completed Phase 3 ALS program, this approach delivered ~100 patients globally, contributed ~30% of total enrollment on a highly competitive study, and saved the sponsor approximately $1.1 million in enrollment cost, with the majority of enrollments originating from Sweden through registry partnerships.

The Challenge: ALS trial recruitment demands more than reach. It demands speed, the right relationships, and a global infrastructure already in place.

A small, geographically dispersed patient pool requires global infrastructure

ALS affects approximately 30,000 people in the US and ~450,000 globally. They are not concentrated in any single country, region, or site. They are spread across national patient organizations, ALS-specific registries, and MND clinical networks in North America, Europe, the Nordics, and Australia. A US-only recruitment strategy leaves a majority of eligible patients unreached. A global strategy without established advocacy and registry partnerships in place is too slow to build during an active trial.

In our last Phase 3 ALS program, Leapcure delivered ~100 patients across 10+ countries, with the majority of enrollments originating from Sweden through pre-established registry partnerships.

Disease progression compresses the eligibility window in real time

ALS patients face progressive functional decline that affects mobility, speech, breathing, and the activities of daily living that determine eligibility for most trials. Every week of recruitment delay shrinks the pool of patients who still meet protocol criteria when they reach site screening. Most recruitment vendors operate on monthly reporting cycles; ALS trials require weekly responsiveness across the channel mix.

Leapcure rebalances advocacy, registry, and digital channels weekly across regions, the approach that contributed ~30% of total enrollment on a highly competitive Phase 3 study.

Multi-country site coordination is where most ALS trials stall

ALS is almost always a multi-country indication. Site capacity, advocacy access, registry participation, and patient referral patterns vary substantially between the US, EU, Nordic countries, and Australia. Most recruitment vendors cannot maintain consistent engagement across regions. When one country falls behind, the program slows; when several do, the program is at risk.

In the Phase 3 ALS program, Leapcure maintained active enrollment across 10+ countries with channel mix and patient support rebalanced weekly per region.

Family- and caregiver-led decisions require an inclusive recruitment process, not a patient-only one

ALS participation decisions are made by families, not patients alone. Spouses, adult children, and caregivers are central to whether a patient enrolls, stays engaged, and follows through. Most recruitment vendors design their process around the patient as the sole decision-maker, which loses qualified ALS patients whose families haven't been brought into the process.

Leapcure's patient support model includes families and caregivers from first contact through enrollment, the model behind ~$1.1M in sponsor savings on our last Phase 3 ALS program.

Three Channels. One Global Advocacy-Led Strategy for Your ALS Trial.

Every ALS study is different. Leapcure deploys the right mix of advocacy and registry partnerships, precision digital, and family-inclusive patient support, mapped to your protocol, your sites, your geographies, and your timeline. Speed is non-negotiable: in ALS, weeks matter.

1

Activate global advocacy and registry partnerships matched to your ALS protocol

Leapcure activates four recruitment channels: ALS advocacy community outreach (40+ partnerships across national patient organizations, ALS-specific registries, and MND clinical networks), precision digital campaigns (search, Reddit, ALS-community Facebook groups, platform-native advocacy content, mapped to geography and site proximity), a family-inclusive patient support model that keeps patients and caregivers engaged through enrollment, and AEO / AI-search visibility for your study. Channel mix is adapted to the protocol, site locations, country footprint, and patient eligibility criteria of each program.

2

Support patients and caregivers through pre-screening across regions

Every patient is engaged by Leapcure's team, along with their caregiver or family member where appropriate, before being assigned to a site. We assess protocol eligibility, account for the complexity of ALS-specific criteria (including disease duration, functional status thresholds, and current treatment history), and confirm patients and families understand what participation involves. Sites conduct official screening; Leapcure ensures the patients who arrive are informed, prepared, and supported through the process, not referrals that create coordinator work.

3

Optimize weekly across countries based on site engagement

Channel performance and site contact rates are tracked continuously across all participating countries. Advocacy, registry, digital, and patient support contributions are rebalanced weekly based on referral quality, site intake capacity, and protocol progress, a cadence ALS requires because disease progression makes monthly review cycles too slow. In the completed Phase 3 ALS program, this approach contributed ~30% of total enrollment, delivered ~100 patients across 10+ countries, and saved the sponsor approximately $1.1 million in enrollment cost.

Phase 3 ALS Recruitment, Completed. ~100 Patients Across 10+ Countries. ~30% of Total Enrollment. ~$1.1M Saved.

Challenge Context

Indication

Amyotrophic Lateral Sclerosis (ALS), Phase 3

Sites

Active sites across 10+ countries spanning North America, Europe (including the Nordics), and Australia

Challenge

Highly competitive Phase 3 ALS study with a small, geographically dispersed eligible population; complex eligibility criteria affected by ongoing disease progression; multi-country site coordination across NA, EU, Nordics, and Australia; competing concurrent ALS studies; advocacy and registry access required to reach the majority of eligible patients.

Channels Deployed

Targeted advocacy partnerships across 40+ ALS and MND organizations globally, with ALS-specific registry partnerships in Sweden and other Nordic countries enabling rapid high-quality referrals; precision digital mapped to site capacity per region; family-inclusive patient support model coordinated across 10+ countries; weekly channel rebalancing per region.

Results & Metrics

Patients Enrolled

~100 ALS patients enrolled globally by Leapcure across 10+ countries.

Contribution Share

~30% of total enrollment on a highly competitive Phase 3 ALS study, a meaningful share that materially shifted the program's recruitment trajectory rather than supplementing it at the margin.

Cost Savings

~$1.1 million in enrollment cost savings delivered to the sponsor. Note: enrollment cost savings vary by protocol, indication phase, country mix, and channel mix. This figure reflects the specific requirements of this program, not a standard rate.

Geographic Distribution

Recruitment spanned 10+ countries across NA, Europe, and Australia. The majority of enrollments originated from Sweden, where Leapcure's ALS-specific registry partnerships enabled rapid, high-quality patient referrals that other countries' channel mix could not match.

Channel Performance

Targeted advocacy and registry partnerships were the primary enrollment engine. Site engagement challenges in lower-performing countries were managed proactively through weekly channel rebalancing, avoiding the extended recruitment timelines that often result when site capacity and channel mix go unaddressed.

Patient Quality

Advocacy- and registry-warmed referrals arrived informed and prepared for official site screening, with caregivers brought into the process from first contact, reducing coordinator burden and supporting retention through the trial.

Four Channels. Built for ALS. Active Before Your Trial Opens.

Leapcure reaches ALS patients through advocacy and registry partnerships, precision digital campaigns, a family-inclusive patient support model, and a fourth channel competing vendors do not currently offer: AEO and AI-search visibility delivered to your trial.

Channel 1: Global Advocacy + Registry Network

  • •40+ active ALS and motor neuron disease partnerships including national ALS patient advocacy organizations across the US, EU, and Australia; ALS-specific registries in Sweden and other Nordic countries; and broader MND clinical networks that surface patients other strategies overlook.
  • •Targeted advocacy partnerships were the mechanism behind the Phase 3 program's rapid high-quality referrals. The Nordic registry network in particular enabled the majority of enrollments to originate from Sweden.
  • •Content co-developed with advocacy partners positions research as a trusted option for patients and families, not an unsolicited pitch. ALS communities are tightly networked; the wrong outreach approach is recognized quickly and damages future access.

Channel 2: Precision Digital Campaigns

  • •Google search, Reddit, ALS-community Facebook groups, and platform-native advocacy content, optimized for ALS-specific patient and caregiver populations, targeted by geography, disease duration signals, and site proximity.
  • •Digital channels are mapped to site capacity in real time across regions. Referrals are modulated so sites are not overwhelmed and patient quality is maintained.
  • •In ALS, digital is the supporting channel, not the primary one. Advocacy and registry partnerships drive the majority of qualified referrals; digital fills the geographic and demographic gaps the registry network does not reach.

Channel 3: Family-Inclusive Patient Support Model

  • •Every referred ALS patient receives step-by-step guidance from first contact through enrollment, with caregivers and family members included from the first conversation, because ALS participation decisions are family-led.
  • •Patient support accounts for the realities of ALS daily life: progressive functional decline, complex care coordination, mobility and communication accommodations, and the emotional burden carried by both patients and families.
  • •This is the channel behind the Phase 3 program's contribution share. Pre-screened, family-prepared patients who arrived at sites informed and supported is why ~$1.1M in enrollment cost was saved without compromising patient quality.

Channel 4: AEO / AI-Search Visibility for Your Trial

  • •Patients and caregivers increasingly discover ALS clinical trials by asking ChatGPT, Perplexity, and Google's AI Overview 'what ALS trials am I eligible for?' or 'new ALS treatment trials near me'. Most recruitment vendors do not structure for this. Leapcure does.
  • •We structure your trial's digital presence (content, schema, citations, community placements, advocacy-network references) so it appears in AI-generated answers about ALS trials.
  • •This is a capability competing recruitment vendors do not currently offer. For ALS, where caregivers do significant online research on behalf of patients with declining function, AI-search visibility compounds over the life of your study. The FAQPage schema on this page is one mechanism we use to demonstrate the capability.

Living with ALS? A clinical trial may be an option for you or someone you care for.

If you're living with ALS, or supporting a partner, parent, sibling, or close friend who is, a clinical trial may give access to investigational treatments not yet widely available. We know that ALS doesn't leave much time, and that decisions about research are made together, by families. Leapcure's team provides step-by-step support to both patients and caregivers, coordinates across care teams, and adapts to where you are in the disease journey, not where a protocol assumes you should be.

See if an ALS trial may be right for you or your loved one
Leapcure kangaroo mascot

Leapcure's ALS recruitment team has completed Phase 2 and Phase 3 ALS programs, delivering ~100 patients globally on a Phase 3 study (~30% of total enrollment) and saving the sponsor approximately $1.1 million in enrollment cost across 10+ countries. We deploy advocacy, registry, precision digital, family-inclusive patient support, and AEO / AI-search channels adapted to your protocol, and we can mobilize within 48 hours of program launch.

Talk to our ALS team